167 related articles for article (PubMed ID: 37924638)
1. Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA.
Wu P; He D; Chang H; Zhang X
Endocr Connect; 2023 Dec; 12(12):. PubMed ID: 37924638
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation.
Zhao F; Huang L; Wang Z; Wei F; Xiao T; Liu Q
Front Endocrinol (Lausanne); 2023; 14():1061187. PubMed ID: 36817582
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
5. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
[TBL] [Abstract][Full Text] [Related]
6. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
[TBL] [Abstract][Full Text] [Related]
7. A real-world, population-based study of the trends for incidence and prognosis in high-grade neuroendocrine tumor of cervix.
Yang XL; Guan WJ; Kou LN; Wang MM; Lai H; Wu DJ
Curr Probl Cancer; 2022 Apr; 46(2):100800. PubMed ID: 34838343
[TBL] [Abstract][Full Text] [Related]
8. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
[TBL] [Abstract][Full Text] [Related]
9. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research.
Hu P; Bai J; Liu M; Xue J; Chen T; Li R; Kuai X; Zhao H; Li X; Tian Y; Sun W; Xiong Y; Tang Q
Gastric Cancer; 2020 Jul; 23(4):591-599. PubMed ID: 32026156
[TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin Lymphoma - Nodal and Extranodal: 20-Year Comparative Mortality, Survival & Biologic Behavior Analysis by Age, Sex, Race, Stage, Cell Morphology/Histology, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 384,651 Total NHL Cases Including 261,144 Nodal and 123,507 Extranodal Cases for Diagnosis Years 1975-2016: (SEER*Stat 8.3.6).
Milano AF
J Insur Med; 2023 Jul; 50(1):1-35. PubMed ID: 37725503
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
[TBL] [Abstract][Full Text] [Related]
12. Incidence and prognostic nomogram for resected non-small cell neuroendocrine tumor: A population-based respective study in China and the SEER database.
Liu Y; Yang M; Pang Z; Zhao X; Ma G; Zhao Q; Du J
Heliyon; 2023 Apr; 9(4):e15319. PubMed ID: 37089398
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological trends, relative survival, and prognosis risk factors of WHO Grade III gliomas: A population-based study.
Fang JH; Lin DD; Deng XY; Li DD; Sheng HS; Lin J; Zhang N; Yin B
Cancer Med; 2019 Jun; 8(6):3286-3295. PubMed ID: 31016895
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer epidemiology and prognostic factors in the United States.
Abudoubari S; Bu K; Mei Y; Maimaitiyiming A; An H; Tao N
Front Oncol; 2023; 13():1142976. PubMed ID: 37901326
[TBL] [Abstract][Full Text] [Related]
15. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database.
Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G
BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241
[TBL] [Abstract][Full Text] [Related]
16. Incidence, survival, and prognostic factors for patients with gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study.
Xu B; Zhang F; Wu R; Peng Y; Mao Z; Tong S
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15657-15669. PubMed ID: 37656242
[TBL] [Abstract][Full Text] [Related]
17. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531).
Mocellin S; Nitti D
Ann Oncol; 2013 Dec; 24(12):3040-4. PubMed ID: 24050954
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a nomogram prognostic model for patients with neuroendocrine tumors of the thymus.
Tang JY; Gao HJ; Shi GD; Guo XK; Yu WQ; Wang HF; Wei YC
Thorac Cancer; 2020 Sep; 11(9):2457-2464. PubMed ID: 32656987
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States.
Shah S; Gosain R; Groman A; Gosain R; Dasari A; Halfdanarson TR; Mukherjee S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
